Stuart Poulton - Aug 15, 2022 Form 3 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: EVP, Chief Development Officer
Signature: /s/Nancy Smith, Attorney-in-Fact for Stuart Poulton
Stock symbol: KPTI
Transactions as of: Aug 15, 2022
Transactions value $: $0
Form type: 3
Date filed: 8/19/2022, 04:15 PM
Next filing: Feb 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	KPTI	Common Stock						70K	Aug 15, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KPTI	Stock Option (right to buy)							Aug 15, 2022	Common Stock	65K	$10.33	Direct	F2
holding	KPTI	Stock Option (right to buy)							Aug 15, 2022	Common Stock	45K	$4.61	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents (i) the award of 45,000 restricted stock units ("RSUs") granted on February 28, 2022 pursuant to the 2022 Inducement Stock Incentive Plan, which vest in four equal installments beginning February 28, 2023 and (ii) the award of 25,000 RSUs granted on July 27, 2022 pursuant to the 2022 Equity Incentive Plan, which vest in four equal annual installments beginning July 27, 2023. The RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
F2	This option was granted on February 28, 2022 pursuant to the 2022 Inducement Stock Incentive Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3	This option was granted on July 27, 2022 pursuant to the 2022 Equity Incentive Plan. The shares underlying this option vest as to 25% of the shares on July 27, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.